31 results about "Calciferols" patented technology

A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.

The present invention relates to a method for enzymatic resolution and preparation of compound 1A, more precisely, the enantiomer separation and recycling method is to first treat compound 1 or 9 with enzymes to obtain compound 1A and compound 7; Selective saponification, oxidation, reduction to obtain compound 1; the obtained compound 1 can enter the cycle of step a-d or a-e again to achieve the purpose of enantiomeric resolution and recycling.

The invention discloses a new preparation method of a derivative A of a key Ayr calciferol intermediate (Z)-2-((3R,4R,5R)-3,5-dihydroxy-4-(3-hydroxy-propoxy)-2-methylene cyclohexyl) ethanol. The method comprises the following steps: performing 3,5-hydroxy protection on a compound 1 serving as a starting material, then reacting the protected compound 1 with R2O(CH2)3X to protect 4-hydroxy, oxidizing with a permanganate to obtain 1,2-hydroxy, performing further oxidation and wittig reaction to obtain 2-methylene, reducing, oxidizing, reacting the oxidized product with trimethyl silicon-based ethyl acetate, and performing DiBAL-H reduction to obtain a compound A. Compared with the prior art, illumination reaction is not used in the new route, so that the operation is simple and amplification is facilitated; and the used raw materials are cheap and readily available natural products, and all chiral centers are introduced from the raw materials, so the cost is low and the quality of the compound A is easy to control.

The invention discloses a content calculation method of a doxercalciferol injection. The method comprises: destroying doxercalciferol by means of a sodium hydroxide water solution to generate a doxercalciferol precursor and 5,6-trans-doxercalciferol, and doxercalciferol and 5,6-trans-doxercalciferol response factors under given chromatographic conditions; calculating the concentration of a doxercalciferol standard substance before destroying, the concentration of the 5,6-trans-doxercalciferol generated after destroying, and the concentration of the non-destroyed doxercalciferol, so as to obtain the concentration of the doxercalciferol precursor after destroying; calculating a precursor response factor according to the peak area of the doxercalciferol precursor after destroying, so that the precursor response factor can be converted into a correction factor of the doxercalciferol, and the correction factor can be directly substituted for calculation when the content of the injection is tested. The method has operability through practice test, the degree of transforming the doxercalciferol into the precursor is not required, the accuracy is high, the method is simple and convenient, and the content of the doxercalciferol in the injection can be effectively controlled.

We disclose treating hyperglycemia in a human with 25-hydroxyyitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.